Fda accepts dupixent® (dupilumab) for priority review in adults with prurigo nodularis

Tarrytown, n.y. and paris , may 31, 2022 /prnewswire/ -- dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the u.s., if approved regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the u.s. food and drug administration (fda) has accepted for priority review the supplemental biologics license application (sbla) for dupixent® medical (dupilumab) to treat adults with prurigo nodularis, a chronic skin disease that causes extreme itch and inflammatory skin lesions (nodules).
REGN Ratings Summary
REGN Quant Ranking